In:
Eurosurveillance, European Centre for Disease Control and Prevention (ECDC), Vol. 28, No. 7 ( 2023-02-16)
Abstract:
We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18–59-year-olds and 14% in 60–85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.
Type of Medium:
Online Resource
ISSN:
1560-7917
DOI:
10.2807/1560-7917.ES.2023.28.7.2300087
Language:
English
Publisher:
European Centre for Disease Control and Prevention (ECDC)
Publication Date:
2023
detail.hit.zdb_id:
2059112-3